Clinical trials: Personalized Cancer Vaccine
Pancreatic Cancer
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected…
- Trial name
- NCT06156267
- Testing
- Adebrelimab, mRNA tumor vaccines
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Gastric Cancer
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer
This trial is an investigator-initiated, single-center, open-label, single-arm exploratory study of mRNA neoantigen tumor vaccine in the treatment of advanced gastric cancer, including two phases: dose escalation and dose…
- Trial name
- NCT05227378
- Testing
- neoantigen tumor vaccine with or without PD-1/L1
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shen Lin
Advanced Cancer, Metastatic Cancer
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden
The study is to investigate the safety and efficacy of dendritic cells vaccines pulsed with autologous whole tumor cell lysate for treating advanced solid tumor patients with high tumor mutation burden.
- Trial name
- NCT03671720
- Testing
- personalized DC vaccine
- Where
- China
- Sponsor
- Capital Medical University
Unmethylated Glioblastoma
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly…
- Trial name
- NCT05743595
- Testing
- Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Refractory Tumor, Solid Tumor
Neoantigen Derived DCs as Cancer Treatment
Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit.
- Trial name
- NCT05767684
- Testing
- Dendritic Cell Vaccine, Lenvatinib, Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- National Health Research Institutes, Taiwan
Glioblastoma
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)
Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly…
- Trial name
- PERCELLVAC (NCT02709616)
- Testing
- Personalized cellular vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangdong 999 Brain Hospital
Cancer, Solid Tumor
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
- Trial name
- NCT05741242
- Testing
- Personalized Synthetic Long Peptide Vaccine
- Where
- 6 sites in United States
- Volunteers
- 136 people
- Sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Melanoma
IVAC MUTANOME Phase I Clinical Trial
Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002…
- Trial name
- NCT02035956
- Testing
- IVAC MUTANOME, RBL001/RBL002
- Where
- 3 sites in Austria, Germany
- Volunteers
- 15 people
- Sponsor
- BioNTech RNA Pharmaceuticals GmbH
Urothelial/Bladder Cancer, Nos
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor…
- Trial name
- NCT03359239
- Testing
- Atezolizumab, PGV001, Poly ICLC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Galsky
Glioblastoma
Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
The treatment option for recurrent glioblastoma is limited. Immune cell based therapy for glioblastoma has shown some efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of…
- Trial name
- PerCellVac2 (NCT02808364)
- Testing
- Personalized cellular vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangdong 999 Brain Hospital
Posto Perative Hepatocellular Carcinoma
Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
This is an open, one-arm study to evaluate the safety and efficacy of mRNA personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with Sintilimab injection for adjuvant prevention of postoperative…
- Trial name
- NCT05761717
- Testing
- Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
- Volunteers
- 67 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced NSCLC
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded dendritic cell (DC) vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06751849
- Testing
- Radiotherapy, PD-1 inhibitor, Neoantigen-loaded DC vaccine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Melanoma
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
This research study is evaluating a new type of melanoma vaccine called "Personalized NeoAntigen Cancer Vaccine". The purpose of this study is to determine if it is possible to make and administer safely a vaccine against…
- Trial name
- NCT01970358
- Testing
- Poly-ICLC, Peptides
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Patrick Ott, MD, PhD
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Neoantigen Cancer Vaccine
The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03639714
- Testing
- GRT-C901, GRT-R902, nivolumab
- Where
- 11 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Gritstone bio, Inc.
Treatment, Neoantigen
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
This is a clinical study of personalized self-DC vaccine targeting neo-antigen (Neo-DC vaccine) in the treatment of advanced solid tumors.
- Conditions
- Treatment, Neoantigen, Vaccine, Solid Tumor Cancer
- Trial name
- Neo-DCV-001 (NCT06682117)
- Testing
- DC Vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
The purpose of this study is to determine the safety and the immunological, radiological, and pathological response of the personalized anti-cancer vaccine AlloVax(TM) in patients with refractory Hepatocellular Carcinoma (HCC)…
- Trial name
- NCT01995227
- Testing
- AlloVax, CRCL, AlloStim
- Where
- Israel
- Sponsor
- Mirror Biologics, Inc.
Advanced Pancreatic Cancer
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of…
- Trial name
- NCT05916261
- Testing
- Personalized neoantigen tumor vaccine
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Ruijin Hospital
Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: Personalized NeoAntigen Vaccine Poly-ICLC…
- Trial name
- NCT03219450
- Testing
- NeoVax, Cyclophosphamide, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Triple Negative Breast Cancer
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells
In this project, the investigators propose the first clinical study in Colombia of vaccination of patients with triple-negative breast cancer (TNBC) using synthetic peptides that contain mutations of the tumor itself that will be…
- Trial name
- NCT04105582
- Testing
- Neo-antigen pulsed Dendritic cell
- Where
- Colombia
- Volunteers
- 5 people
- Sponsor
- Universidad Nacional de Colombia